P-tau217 Blood Test: Normal Range, Results Explained, and What High Levels Mean

Sample type: Plasma

Other names: P-tau217, Phospho-tau 217, Phosphorylated Tau 217, p-tau 217, Plasma p-tau217, P-Tau217 Blood Test, ptau217, ptau 217, p tau217, p tau 217, P-Tau217 Normal Range, P-Tau217 Blood Test Results, Phospho-Tau 217 Plasma, Tau Protein Phosphorylated 217, AD-Detect p-tau217, AD-Detect ptau217 Plasma, Lumipulse p-tau217, ALZpath p-tau217, P-tau217/Aβ42 Ratio, Phospho-tau217, Tau 217, P-tau217 Alzheimer's Test, P-tau217 High, P-tau217 Levels, P-tau217 Range, P-tau217 Results, Fosfotau 217 (Spanish), Plasma Tau 217

Optimal result: 0 – 0.18 pg/mL

High p-tau217 means Alzheimer's-related amyloid and tau pathology is likely present in the brain. The result supports — but does not confirm — Alzheimer's disease, and must be interpreted alongside cognitive testing, symptoms, and clinical history. Your clinician may recommend confirmatory amyloid PET imaging or CSF biomarkers. A positive p-tau217 may also support eligibility for disease-modifying treatments such as lecanemab or donanemab, which require confirmed amyloid pathology.

Low p-tau217 makes Alzheimer's-type amyloid and tau pathology unlikely at the time of testing. This is a reassuring result in a patient being evaluated for possible Alzheimer's disease, and may help redirect evaluation toward other potential causes of cognitive symptoms. A negative result does not completely exclude early Alzheimer's disease and should always be interpreted alongside clinical assessment.

P-tau217 is a phosphorylated form of the tau protein measured in blood plasma. Elevated levels indicate Alzheimer's-type amyloid and tau pathology in the brain. On the Lumipulse platform (the most widely used clinical assay), results below ~0.18–0.20 pg/mL are typically negative; above ~0.32–0.33 pg/mL are typically positive; values in between are indeterminate. Cutoffs are assay-specific — always use the reference range on your own report.

QUICK ANSWER

P-tau217 (phosphorylated tau at threonine 217) is a blood plasma biomarker that reflects Alzheimer's disease-related brain changes — specifically the presence of amyloid plaques and tau pathology — before or alongside symptoms.

Reference ranges vary by assay and lab. The most widely used clinical platform is Lumipulse (Fujirebio), for which Mayo Clinic and published validation studies use these approximate thresholds:

Result Lumipulse p-tau217 (pg/mL) Interpretation
Negative ≤ 0.18–0.20 AD-type pathology unlikely at this time
Indeterminate / Gray zone 0.18–0.32 Borderline — confirmatory testing or repeat may be needed
Positive ≥ 0.32–0.33 AD-type amyloid/tau pathology likely

Always use the reference range and cutoffs printed on your own lab report. Different assay platforms (Lumipulse, ALZpath, C2N AD-Detect, mass spectrometry-based) use different cutoff values that are not interchangeable.

If you have a specific Lumipulse result — what it typically means:

Example result (pg/mL) Typical interpretation on Lumipulse
0.10–0.12 Clearly negative — AD-type pathology unlikely
0.18 Near the negative threshold — typically negative
0.22–0.25 Indeterminate / gray zone — further evaluation often recommended
0.30–0.32 Near the positive threshold — borderline; clinician judgment required
0.40+ Clearly positive — AD-type pathology likely

These values apply to the Lumipulse platform only and cannot be compared to results from AD-Detect, ALZpath, or other assays.


Key takeaway: A positive p-tau217 result increases the likelihood of Alzheimer's-type pathology — it does not confirm an Alzheimer's disease diagnosis. Interpretation requires the clinical picture, cognitive testing, and often confirmatory testing.


WHAT IS P-TAU217?

Tau is a protein that stabilizes structures inside neurons. In Alzheimer's disease, tau becomes abnormally phosphorylated at specific sites — including threonine 217 — and forms toxic tangles inside brain cells. Phosphorylated tau-217 (p-tau217) leaks into the bloodstream as this process occurs, making it detectable by a blood test.

Why p-tau217 specifically?

  • P-tau217 rises earlier and more steeply in Alzheimer's disease than other phospho-tau variants (p-tau181, p-tau231)
  • It reflects both amyloid plaque formation and tau tangle pathology simultaneously
  • Its plasma levels correlate strongly with amyloid PET and CSF biomarker results
  • In head-to-head comparisons, p-tau217 generally shows higher diagnostic accuracy than p-tau181 for identifying AD-type pathology

FDA clearance: The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio assay received FDA 510(k) clearance on May 16, 2025 — the first FDA-cleared blood-based diagnostic test to aid in identifying amyloid pathology associated with Alzheimer's disease. Labcorp launched nationwide availability of the test in August 2025. This marked a major shift from primarily research and specialty-center use toward broad clinical availability in the US.


WHAT DOES A HIGH P-TAU217 MEAN?

A high p-tau217 (above the positive cutoff for your assay) means Alzheimer's-type amyloid and tau pathology is likely present in the brain. The higher the value above the positive threshold, the stronger the signal.

What this means clinically:

  • The brain changes associated with Alzheimer's disease are likely occurring
  • It supports — but does not confirm — a clinical diagnosis of Alzheimer's disease
  • Your clinician may recommend confirmatory testing (amyloid PET scan or CSF biomarkers) if the result would change management
  • It may support eligibility for Alzheimer's disease-modifying treatments (lecanemab, donanemab) which require confirmed amyloid pathology

What a high result does not mean:

  • It does not mean you will definitely develop Alzheimer's dementia
  • It does not measure the rate of progression
  • It is not a standalone diagnosis — clinical symptoms and cognitive testing are always required

WHAT DOES A LOW P-TAU217 MEAN?

A low p-tau217 (below the negative cutoff for your assay) makes Alzheimer's-type amyloid and tau pathology unlikely at this time. It is a reassuring result in a patient being evaluated for possible Alzheimer's disease.

What this means clinically:

  • AD-type pathology is less likely as the explanation for current cognitive symptoms
  • It may redirect evaluation toward other causes of cognitive change (vascular dementia, Lewy body dementia, depression, metabolic causes)
  • It does not completely exclude early or preclinical Alzheimer's disease

A negative result, like all biomarker tests, is most meaningful when combined with clinical assessment and cognitive testing.


WHAT DOES AN INDETERMINATE / GRAY ZONE RESULT MEAN?

Many labs report p-tau217 using a two-cutoff approach — a lower negative threshold and a higher positive threshold — with a gray zone in between. This is intentional.

Why two cutoffs? The two-cutoff strategy improves overall diagnostic accuracy by reserving the highest-confidence "positive" and "negative" calls for results clearly outside the ambiguous middle range. Studies show that roughly 70–85% of patients can be classified with high confidence (negative or positive) using this approach, while 15–30% fall in the intermediate zone.

What to do with an indeterminate result:

  • Your clinician will weigh the result alongside cognitive testing, symptoms, and other biomarkers (Aβ42, p-tau217/Aβ42 ratio, NfL)
  • Repeat testing after 6–12 months may be recommended if symptoms progress
  • Amyloid PET or CSF biomarkers may be ordered for definitive classification
  • An indeterminate result is not a "bad" result — it reflects honest uncertainty rather than failure of the test

WHY DO REFERENCE RANGES DIFFER BY ASSAY?

The same patient's blood measured on different p-tau217 platforms will produce different absolute numbers. This is because each assay uses different antibodies, detection methods, and calibrators.

The major commercial platforms and their characteristics:

Platform Manufacturer Method Common clinical use
Lumipulse Fujirebio Chemiluminescent immunoassay (CLEIA) FDA-cleared; widely used in US hospital labs
ALZpath Simoa ALZpath Single molecule array (Simoa) High sensitivity; used in research and specialty clinics
AD-Detect C2N Diagnostics Mass spectrometry (%p-tau217) Reports as percentage, not absolute pg/mL
PrecivityAD2 C2N Diagnostics Mass spectrometry + algorithm Combines %p-tau217 with Aβ42/40 ratio

This is why the ranges differ: An "indeterminate" result on Lumipulse may correspond to a different absolute number than an "indeterminate" on ALZpath. Do not attempt to apply one platform's cutoffs to another platform's results.


P-TAU217 AND THE P-TAU217/Aβ42 RATIO

Some labs report the p-tau217/Aβ42 ratio alongside or instead of p-tau217 alone. Adding Aβ42 improves discrimination because:

  • Aβ42 falls as amyloid plaques accumulate (it gets "trapped" in the brain)
  • P-tau217 rises as pathology advances
  • The ratio therefore moves in a direction more powerfully than either marker alone

The Lumipulse FDA-cleared assay specifically measures the p-tau217/Aβ42 ratio. A high ratio (elevated p-tau217 combined with low Aβ42) strengthens the indication of AD pathology beyond p-tau217 alone.


CAN P-TAU217 BE ELEVATED BEFORE SYMPTOMS APPEAR?

Yes. P-tau217 can become abnormal years — potentially a decade or more — before dementia develops. This is one of the most clinically important features of the biomarker.

Alzheimer's disease pathology (amyloid plaques and tau tangles) begins accumulating in the brain well before memory loss or cognitive symptoms become apparent. P-tau217 reflects this underlying biological process, not the severity of current memory loss. This means:

  • A person with elevated p-tau217 may currently have mild cognitive impairment (MCI), subjective memory concerns, or even no obvious symptoms at the time of testing
  • An elevated result in a person without symptoms does not mean dementia is imminent — it indicates the biological process is underway
  • Early detection is the point: identifying Alzheimer's-type pathology before significant neuronal loss has occurred is precisely when disease-modifying treatments may have the greatest potential benefit

What presymptomatic elevation does not mean:

  • It does not predict with certainty that dementia will develop — not all people with amyloid pathology progress to symptomatic disease
  • It does not indicate how quickly symptoms will appear
  • It does not mean that immediate treatment is required in all cases — decisions about intervention depend on the full clinical picture

WHEN IS THE P-TAU217 TEST ORDERED?

P-tau217 is typically ordered in adults with:

  • New or progressive memory and thinking changes under evaluation for possible Alzheimer's disease
  • Mild cognitive impairment (MCI) where clarifying the underlying cause would change management
  • Atypical presentations where Alzheimer's vs. another dementia is unclear
  • Pre-treatment workup for patients being considered for amyloid-targeting therapies (lecanemab, donanemab)
  • Situations where amyloid PET or lumbar puncture is not accessible, not desired, or has already been deferred

The test is not currently recommended as routine screening in cognitively normal individuals without symptoms. Its performance in the general asymptomatic population is less well established.


WHEN TO FOLLOW UP

Discuss your p-tau217 result with a clinician if:

  • Your result is in the positive range — confirmatory amyloid PET or CSF testing may be recommended
  • Your result is indeterminate — repeat testing or additional biomarkers may be ordered
  • Your result is negative but symptoms are progressing — other causes of cognitive change need evaluation
  • You are considering or already on Alzheimer's disease-modifying therapy

BOTTOM LINE

Bottom line: P-tau217 is a blood plasma biomarker that identifies Alzheimer's-related brain changes. A positive result (above the assay-specific cutoff) increases the likelihood of AD pathology; a negative result makes it less likely. Cutoffs differ significantly between platforms — Lumipulse, ALZpath, AD-Detect, and PrecivityAD2 are not interchangeable. An indeterminate (gray zone) result is common and prompts further evaluation rather than a definitive conclusion. P-tau217 is an aid to diagnosis, not a diagnosis itself.

p-tau217
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond p-tau217 — 10,000+ markers explained
One p-tau217 result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time

Frequently Asked Questions

Can p-tau217 go back to normal?
This is an active area of research. Early data from Alzheimer's disease-modifying treatment trials (lecanemab, donanemab) suggest that successful amyloid removal is associated with reductions in p-tau217 levels, though the magnitude of change and its clinical meaning are still being characterized. A single p-tau217 result should not be interpreted in isolation — trends over time and treatment context matter. Whether a decline in p-tau217 on treatment translates to meaningful cognitive benefit remains under active investigation. Do not interpret a declining p-tau217 value as confirmation that a treatment is working without clinical guidance.
What is a normal p-tau217 range?
Reference ranges are assay-specific and not interchangeable between platforms. On the most widely used clinical platform (Lumipulse/Fujirebio), published validation studies and clinical use at Mayo Clinic classify results as: negative (≤ ~0.18–0.20 pg/mL), indeterminate (~0.18–0.32 pg/mL), or positive (≥ ~0.32–0.33 pg/mL). Always use the reference range printed on your own lab report, which will show the cutoffs for the specific assay used.
What does a high p-tau217 mean?
A high p-tau217 (above the positive cutoff on your report) indicates that Alzheimer's-type amyloid and tau pathology is likely present in the brain. It supports a diagnosis of Alzheimer's disease when combined with clinical symptoms and cognitive testing, but does not confirm it alone. Your clinician may recommend amyloid PET imaging or CSF biomarkers for confirmation if the result would change your treatment plan.
What does it mean if my p-tau217 is in the gray zone?
A gray zone or indeterminate p-tau217 result falls between the negative and positive cutoffs. Roughly 15–30% of tested patients fall in this range. It reflects genuine uncertainty and typically prompts further evaluation — either repeat testing after symptom progression, additional biomarkers (Aβ42, NfL), or amyloid PET imaging. An indeterminate result is not a "positive" result.
Is the p-tau217 test the same as an Alzheimer's diagnosis?
No. P-tau217 is a diagnostic aid, not a diagnosis. A positive result increases the likelihood that Alzheimer's-related brain changes are present, but diagnosis requires integration of the result with clinical symptoms, cognitive testing, history, and often confirmatory testing. A negative result makes Alzheimer's less likely but does not completely exclude it.
What is the difference between p-tau217 and p-tau181?
Both are phosphorylated forms of the tau protein used as Alzheimer's biomarkers, but p-tau217 generally shows higher diagnostic accuracy in published studies. P-tau217 rises earlier and more steeply in Alzheimer's disease and correlates more strongly with amyloid PET results. Many specialty clinics now prefer p-tau217 when it is available.
Do I still need a PET scan or lumbar puncture after a p-tau217 result?
Sometimes. P-tau217 can rule in or rule out Alzheimer's-type pathology for most patients with confidence, potentially avoiding PET or lumbar puncture. However, confirmatory testing may still be recommended when results are borderline (gray zone), when the clinical picture is atypical, or when confirmation would directly change treatment decisions — particularly for Alzheimer's disease-modifying therapies that require confirmed amyloid pathology.
Why does my number look different from ranges I find online?
Different assay platforms produce different absolute numbers for the same patient. Lumipulse reports in pg/mL (typically 0.05–0.50+ range); AD-Detect (C2N) reports as a percentage (%p-tau217) in a different numeric range; ALZpath Simoa uses yet another scale. Never apply cutoffs from one platform to results from another. The reference range on your own report is the only valid interpretation guide.
What if my p-tau217 is intermediate but my amyloid PET scan is positive?
An intermediate p-tau217 result does not rule out Alzheimer's-related pathology. Blood biomarkers are screening and triage tools, while amyloid PET imaging directly measures amyloid deposition in the brain. A positive amyloid PET scan generally carries greater diagnostic weight than an intermediate blood biomarker result. It is possible to have an intermediate p-tau217 result while already demonstrating amyloid pathology on PET imaging, particularly in early disease stages.
Can kidney disease affect p-tau217 results?
Reduced kidney function may increase circulating p-tau217 levels and should be considered when interpreting results. Clinicians generally evaluate p-tau217 alongside kidney function markers such as creatinine, cystatin C, and eGFR.
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

  1. Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
    Brain. · 2025 View source ↗
  2. Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
    Alzheimers Dement (Amst). · 2025 View source ↗
  3. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform
    Nat Med. · 2025 View source ↗
  4. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
    Neurology. · 2019 View source ↗
Article Review Log
Last reviewed June 1, 2026
Originally published June 1, 2026
Reviewed by HealthMatters Editorial Team
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro